Paradigm is building a new platform to streamline clinical trials and expand patient access to potentially life-saving therapies. The company's software aims to integrate with electronic medical records, making it easier for doctors and researchers to recruit diverse patient populations and reduce administrative burdens. By enabling community health providers, who serve the majority of cancer patients, to participate in trials, Paradigm seeks to address the current reality where less than 5% of eligible patients enroll in clinical studies.
CEO Kent Thoelke spent over 25 years overseeing drug development at various organizations and experienced the inefficiencies of the current system firsthand. Co-founder Jonathan Hirsch previously founded a cancer data analytics company. The leadership team also includes Kenneth Frazier, former CEO of pharmaceutical giant Merck. This seasoned team has rapidly raised $200 million from top biotech and healthcare investors like ARCH Venture Partners and General Catalyst.
Paradigm is initially focused on oncology trials and has launched collaborations with major pharmaceutical companies like Bristol Myers Squibb. Employees joining at this stage, with just over 100 people and early partnerships in place, will help define Paradigm's culture and trajectory as it aims to become the leading platform powering faster, more inclusive clinical trials. However, meaningfully changing entrenched systems in healthcare is never easy. Paradigm will need to prove it can compel adoption from established contract research organizations and provider networks to realize its mission.
2022
Founded
100-250
Employees
Series A
Stage
$400M
Latest Valuation
$200-400M
Total Funding
Jan 27 2023
Last Fundraise
Why is the rating
Top Previous Employers

Deep Lens

Syapse

Cardinal Health

Flatiron Health
Investors

General Catalyst
Airbnb, Snap, Gusto